




Supplementary Fig. S7 ASO1-TMO and ASO2-TMO inhibit MIA PaCa-2 cell growth in a xenograft model. a, Mice were weighed every day. **b,** Quantification of PKM splice switching in Figure 6f. **c,** Quantification of PKM1 and PKM2 in Figure 6h, normalized to Vinculin. **d,** Lactic acid concentration in samples prepared from tumors from mice treated with SCR-TMO, ASO1-TMO, or ASO2-TMO. **e,** Representative IF images of tumor sections for PKM2 (green) or ASO antibody (red) and nuclei with DAPI (blue) from the same tumor samples as in panel d. Scale bar, 50 μ m. **f,** Representative IF images of tumor sections for PKM1 (green) or Ki67 proliferation marker (red) and nuclei (blue) from the same tumor samples as in panel d. Scale bar, 50 μ m. **g,** Summary data from Fig. 5i) of Ki67⁺

and PKM2⁺ cell numbers normalized to DAPI⁺ nuclei for each treatment group (n = 5 random fields). **h**, Representative H&E images of kidney, duodenum, liver, and muscle from the same animals as in panel d. Scale bar, 500 μ m. **i**, Representative IF images of duodenum section for PKM2 (green) or proliferation marker (Ki67, red) and nuclei (blue) from the same animals as in panel d. Scale bar, 50 μ m. **j-l**, RT-PCR and quantification of *PKM* splicing in kidney and duodenum. **k**, glomeruli per field from the same animals as in panel d. Statistical analysis: unpaired two-sided t-test (b, c, d, g, k, m); two-way ANOVA (a); Pearson correlation analysis (g).